Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals

Pediatric Infectious Disease Journal

Volumn 31, Issue 2, 2012, Pages 164-170

  Knapp, Katherine M ^a   Brogly, Susan B ^b   Muenz, Daniel G ^c   Spiegel, Hans M L ^d   Conway, Daniel H ^e   Scott, Gwendolyn B ^f   Talbot, Jeffrey T ^b   Shapiro, David E ^c,g   Read, Jennifer S ^h  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Antiretroviral; Congenital anomalies; HIV; In utero exposure

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; CARDIOVASCULAR MALFORMATION; CENTRAL NERVOUS SYSTEM MALFORMATION; CONGENITAL MALFORMATION; CRANIOFACIAL MALFORMATION; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INFANT; INFANT DISEASE; KIDNEY MALFORMATION; LIVE BIRTH; MAJOR CLINICAL STUDY; MUSCLE MALFORMATION; NEWBORN; PRENATAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; SKELETON MALFORMATION; UROGENITAL TRACT MALFORMATION;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CONGENITAL ABNORMALITIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; YOUNG ADULT;

EID: 84858159244     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318235c7aa     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Recomm Rep. 1994;43(RR-11):1-20.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180. (Pubitemid 24331334)
3. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996;335:1621-1629. (Pubitemid 26392726)
4. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov. 2003;2:812-822. (Pubitemid 37361813)
5. Venhoff N, Walker UA. Mitochondrial disease in the offspring as a result of antiretroviral therapy. Expert Opin Drug Saf. 2006;5:373-381.
6. Aldrovandi GM, Chu C, Shearer WT, et al. Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women. Pediatrics. 2009;124:e1189-e1197.
7. Divi RL, Einem TL, Fletcher SL, et al. Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs). Toxicol Sci. 2010;118:191-201.
8. Brogly SB, Dimauro S, Vandyke R, et al. Transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children. AIDS Res Hum Retroviruses. 2011;27:777-783.
9. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudinezidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083-2093.
10. Cooper ER, Charurat M, Mofenson L, et al. Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494. (Pubitemid 34456340)
11. Dorenbaum A, Cunningham CK, Gelber RD, et al. International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002;288:189-198. (Pubitemid 34755279)
12. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. May 24, 2010:1-117. Available at: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed July 9, 2010.
13. Bristol-Myers Squibb. Sustiva (efavirenz) drug label (2009). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/020972s033, 021360s021lbl.pdf. Accessed July 9, 2010.
14. Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS. 2010;24:1461-1470.
15. Saitoh A, Hull AD, Franklin P, et al. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol. 2005;25:555-556. (Pubitemid 41122407)
16. Fundarò C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002;16:299-300.
17. Centers for Disease Control and Prevention (CDC). Update on overall prevalence of major birth defects - Atlanta, Georgia, 1978-2005. Morb Mortal Wkly Rep. 2008;57:1-5.
18. Hernández-Díaz S, Werler MM, Walker AM, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol. 2001;153:961-968. (Pubitemid 32423782)
19. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006;67:407-412. (Pubitemid 44214962)
20. Richardson MP, Osrin D, Donaghy S, et al. Spinal malformations in the fetuses of HIV infected women receiving combination antiretroviral therapy and co-trimoxazole. Eur J Obstet Gynecol Reprod Biol. 2000;93:215-217.
21. Jungmann EM, Mercey D, DeRuiter A, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect. 2001;77:441- 443.
22. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356:2675-2683. (Pubitemid 47001035)
23. Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88:94-100.
24. Forrester MB, Merz RD. Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986-2002. J Toxicol Environ Health A. 2007;70:7-18. (Pubitemid 46018006)
25. Astley SJ. Profile of the first 1,400 patients receiving diagnostic evaluations for fetal alcohol spectrum disorder at the Washington State Fetal Alcohol Syndrome Diagnostic & Prevention Network. Can J Clin Pharmacol. 2010;17:e132-e164.
26. Bristol-Myers Squibb. Sustiva (efavirenz) drug label (1998). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/1998/20972lbl.pdf. Accessed September 2, 2010.
27. Bristol-Myers Squibb. Sustiva (efavirenz) drug label (2005). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/020972s026, 021360s013lbl.pdf. Accessed July 11, 2011.
28. Brogly SB, Abzug MJ, Watts DH, et al. Birth defects among children born to human immunodeficiency virus-infected women: Pediatric AIDS Clinical Trials Protocols 219 and 219C. Pediatr Infect Dis J. 2010;29:721-727.
29. Canfield MA, Honein MA, Yuskiv N, et al. National estimates and race/ ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol. 2006;76:747-756.
30. Patel D, Thorne C, Fiore S, et al. European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr. 2005;40:116-118. (Pubitemid 41233219)
31. Townsend CL, Willey BA, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS. 2009;23:519-524.
32. Watts DH, Daner L, Handelsman E, et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr. 2007;44:299-305. (Pubitemid 46328346)
33. Joao EC, Calvet GA, Krauss MR, et al. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI Perinatal Study. J Acquir Immune Defic Syndr. 2010;53:176 -185.
34. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2010. Wilmington, NC: Registry Coordinating Center; 2010. Available at: www.APRegistry.com. Accessed July 20, 2010.